MedPage Today April 8, 2024
— Intense demand coupled with high costs may place pressures on CMS for years to come
On March 8, 2024, FDA approved Wegovy (semaglutide) to treat cardiovascular disease risks — heart attack, stroke, and death — for obese or overweight adults with a history of cardiovascular disease, making it the first anti-obesity medication (AOM) to obtain such approval. Studies show that semaglutide reduces heart disease risks when accompanied by blood pressure and cholesterol management and healthy lifestyle counseling. FDA noted that this approval is “a major advance in public health.”
Less than 2 weeks after FDA approved the new indication (semaglutide is also approved for chronic weight management and type 2 diabetes), CMS issued a memorandum stating that Medicare Part...
Today's Sponsors
Today's Sponsor